![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: WFDC3 |
Gene summary for WFDC3 |
![]() |
Gene information | Species | Human | Gene symbol | WFDC3 | Gene ID | 140686 |
Gene name | WAP four-disulfide core domain 3 | |
Gene Alias | WAP14 | |
Cytomap | 20q13.12 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q8IUB2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
140686 | WFDC3 | RNA-P17T-P17T-2 | Human | Lung | IAC | 1.99e-06 | 7.00e-01 | 0.3371 |
140686 | WFDC3 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.48e-03 | 5.59e-01 | 0.3385 |
140686 | WFDC3 | RNA-P17T-P17T-8 | Human | Lung | IAC | 4.12e-03 | 5.21e-01 | 0.3329 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00525478 | Lung | IAC | regulation of peptidase activity | 80/2061 | 461/18723 | 2.39e-05 | 6.50e-04 | 80 |
GO:00525488 | Lung | IAC | regulation of endopeptidase activity | 75/2061 | 432/18723 | 4.18e-05 | 1.01e-03 | 75 |
GO:00458618 | Lung | IAC | negative regulation of proteolysis | 58/2061 | 351/18723 | 1.04e-03 | 1.24e-02 | 58 |
GO:00109518 | Lung | IAC | negative regulation of endopeptidase activity | 41/2061 | 252/18723 | 6.84e-03 | 4.75e-02 | 41 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WFDC3 | SNV | Missense_Mutation | novel | c.193N>C | p.Cys65Arg | p.C65R | Q8IUB2 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
WFDC3 | SNV | Missense_Mutation | rs370827055 | c.558N>T | p.Glu186Asp | p.E186D | Q8IUB2 | protein_coding | tolerated(0.22) | probably_damaging(0.949) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WFDC3 | SNV | Missense_Mutation | rs781761019 | c.673G>A | p.Glu225Lys | p.E225K | Q8IUB2 | protein_coding | tolerated_low_confidence(0.09) | benign(0.003) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
WFDC3 | SNV | Missense_Mutation | rs749135049 | c.467G>A | p.Arg156His | p.R156H | Q8IUB2 | protein_coding | tolerated(1) | benign(0) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WFDC3 | SNV | Missense_Mutation | c.686C>T | p.Pro229Leu | p.P229L | Q8IUB2 | protein_coding | tolerated_low_confidence(0.1) | benign(0.003) | TCGA-CC-A5UE-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
WFDC3 | SNV | Missense_Mutation | c.445N>A | p.Cys149Ser | p.C149S | Q8IUB2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CC-A7IH-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
WFDC3 | SNV | Missense_Mutation | c.61N>A | p.Trp21Arg | p.W21R | Q8IUB2 | protein_coding | tolerated(0.23) | benign(0.213) | TCGA-CC-A7IH-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
WFDC3 | SNV | Missense_Mutation | c.172N>C | p.Thr58Pro | p.T58P | Q8IUB2 | protein_coding | deleterious(0.02) | benign(0.229) | TCGA-LG-A6GG-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
WFDC3 | SNV | Missense_Mutation | rs376220123 | c.502G>A | p.Gly168Ser | p.G168S | Q8IUB2 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-62-A470-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
WFDC3 | SNV | Missense_Mutation | c.653N>T | p.Trp218Leu | p.W218L | Q8IUB2 | protein_coding | tolerated_low_confidence(0.6) | benign(0) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |